Which drug is better, avatrombopag, heltrombopag or eltrombopag?

Avatrombopag, heltrombopag and eltrombopag are all new drugs that have attracted much attention in the field of treating thrombocytopenia in recent years. They are both non-peptide oral thrombopoietin receptor agonists (TPO-RA). By interacting with the transmembrane domain of the human TPO receptor, they stimulate the proliferation and differentiation of the bone marrow megakaryocytic system, thereby promoting the production and release of platelets. However, although these three drugs have similar therapeutic mechanisms, there are significant differences in structure, pharmacokinetics, indications, and safety.

First of all, from the perspective of drug structure, both eltrombopag and heltrombopag contain a hydrazide structure, which can easily form chelates with metal cations, affecting the absorption and efficacy of the drug. Therefore, these two drugs need to be taken on an empty stomach or with a low-fat diet to reduce the impact of food on drug absorption. Avatrombopag, on the other hand, does not have a hydrazide structure and does not chelate with metal cations, so it can be taken under any dietary status and is not affected by food. This feature gives avatrombopag a clear advantage in terms of convenience of medication.

Secondly, in terms of pharmacokinetics, the half-lives of eltrombopag and heltrombopag are relatively short, respectively3.8 hours and 3.5 hours, and they need to be taken once a day to maintain effective blood concentrations. The half-life of avatrombopag is as long as 14.7 hours and can be taken once a week, thus reducing the frequency and inconvenience of patients. However, this also means that avatrombopag remains in the body longer and may require longer monitoring and dose adjustments.

In terms of indications, eltrombopag currently has the most approved indications in China, including primary immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia (CHC-CIT) and severe aplastic anemia (SAA). Hetrombopag is mainly used to treat primary immune thrombocytopenia (ITP) and aplastic anemia (SAA) where the efficacy of simple immunosuppressants is not satisfactory. Avatrombopag currently has relatively few approved indications in China, and is mainly used to treat chronic liver disease-related thrombocytopenia (CLD-CIT). However, this does not mean that a certain drug is necessarily better than other drugs, because different indications have different causes, pathologies, and clinical manifestations, and the appropriate drug needs to be selected according to the patient's specific situation.

Finally, in terms of safety, these three drugs may have serious adverse reactions such as thrombosis, myelofibrosis, platelet rebound, and drug resistance. Therefore, it is necessary to closely monitor the patient's platelet count and drug response during use, and adjust the dose or change drugs in a timely manner to reduce the risk of adverse reactions. In addition, for special groups such as elderly patients, patients with liver function impairment, and patients with renal function impairment, more careful selection and use of these drugs are needed.

To sum up, the three drugs avatrombopag, heltrombopag and eltrombopag have their own advantages and disadvantages, and there is no absolute advantage or disadvantage. The choice of use needs to be comprehensively considered based on the patient's specific situation, indication needs and doctor's recommendations. At the same time, it is also necessary to pay close attention to the adverse reactions of drugs and take timely measures to ensure patient drug safety and therapeutic effects.